ScoreHaematology
CLL International Prognostic Index (CLL-IPI)
Combines genetic, biochemical and clinical data to estimate 5-year survival in chronic lymphocytic leukaemia.
Updated 30 October 2026
When to use it
CLL at diagnosis or before first treatment, to inform prognosis and guide follow-up intensity.
What it needs
- Altered TP53: del(17p) and/or TP53 mutation
- Unmutated IGHV
- Serum β2-microglobulin > 3.5 mg/L
- Clinical stage Binet B–C or Rai I–IV
- Age > 65 years
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Low risk (5-year survival ≈ 93 %) |
| 2–3 | Intermediate risk (5-year survival ≈ 79 %) |
| 4–6 | High risk (5-year survival ≈ 63 %) |
| ≥ 7 | Very high risk (5-year survival ≈ 23 %) |
Practical tip
It was derived in patients treated with chemotherapy or chemoimmunotherapy; with BTKi or venetoclax it discriminates less well, especially between high and very high risk.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
